Modular Medical, Inc. · NASDAQ:MODD
Modular Medical — Investor Presentation (September 2021)
20 slides from Modular Medical's investor presentation, Sep 30, 2021
Slide 1: Investor Presentation
Investor Presentation. OTCQB:MODD
Slide 2: Forward Looking Statements, Other Disclaimers
Forward Looking Statements, Other Disclaimers. THIS SUMMARY IS PROVIDED ON A CONFIDENTIAL AND LIMITED BASIS, SOLELY FOR YOUR USE AS A PART OF YOUR DETERMINATION OF WHETHER TO INVEST IN THE OPPORTUNITY. THIS SUMMARY IS BEING PROVIDED IN RELIANCE UPON SECTION 105(C) OF THE JUMPSTART OUR BUSINESS START
Slide 3: The Future of Diabetes Care is Easy
Type 1's in US 1.6 Million 3 | The Future of Diabetes Care is Easy. Insulin Pumps provide a higher standard of diabetes care. Better glycemic control reduces co-morbidity prevalence, trips to the ER, and leads to higher quality of life. Despite decades of advances in insulin delivery technology, onl
Slide 4: An Unmet Need in Type 1 Diabetes Care
An Unmet Need in Type 1 Diabetes Care. There are 1.6 million individuals with Type 1 Diabetes in the US. 100% of patient population require daily insulin injection. Only 1 out of 3 currently use an insulin pump. Pumping 32% of population utilizes insulin pumps for diabetes management 32% Multiple Da
Slide 5: New kinds of offerings attract a new kind of user
New kinds of offerings attract a new kind of user. Abbott Freestyle Libre made continuous glucose monitoring easier and more affordable. This expanded the product category and doubled its size. We believe the insulin pump market is ready for a similar transition. 5 | FreeStyle Libre vs. Dexcom Reven
Slide 6: Expanding access to pumps requires a new kind of pump
Expanding access to pumps requires a new kind of pump. Time Insulin pumps on the market today require a substantial amount of time to learn and manage ongoing therapy Money High out of pocket costs of today's pumps place these technologies out of reach for a large part of the population Technology F
Slide 7: Introducing MOD1
Introducing MOD1 90 Day Reusable Designed to meet patient needs: ? Removable ? No External Controller Required ? Push Button to Bolus ? No Charging or Battery Replacement ? Easy to Use ? Learn to Use at Home ? 3 Day Consumable $0 Upfront Cost to Patient or Payor 20% Discount to Omnipod New microflui
Slide 8: Technology that Transforms Diabetes Care
Technology that Transforms Diabetes Care. (and diabetes company models) $4,086 Revenue Per Patient/Year1 8 | 78% Gross Margins Traditional Pumps Use Expensive Machining and Complex Modalities To PumpCoImnpsaunlyin 5 Years Development: Same Precision, Off the Shelf, High Volume Components from consum
Slide 9: Unit Economics: Profitable From the First Sale
Unit Economics. Profitable From the First Sale 180 Day Re-Usable Price: FREE Cost: $34 First month: 1 Re-Usable + 10 Disposables Price: $349.20 Cost: $34 + $76.80 = $111.80 Gross Profit: $238.40 68% Profit Margin 3 Day Disposable Subsequent Months: 10 Disposables Price: $34.92* Cost: $7.68 Price: $3
Slide 10: Designed to make adoption easy
Designed to make adoption easy. Telehealth Optimized 10 | 10 2020 saw personal telehealth go from beta test to mainstream. Customers and providers have become comfortable with it. Provider ? Direct sales Force Focused on Providers ? Free Samples to Encourage Trial ? Point of Prescription Couponing P
Slide 11: Payor Preferred
Payor Preferred. National Payor Survey Retained ISA to perform National Payors Survey on 1/3 of all commercial lives in US (50 million lives) 11 | 10 Modular Medical products are designed to attain preferential reimbursement and avoid the coverage pitfalls many other pumps have experienced. Payor Be
Slide 12: Milestones to Launch
Milestones to Launch. Approval: 510(k) Predicate device pathway for FDA clearance. Same label as Omnipod. Testing is based on benchtop tests, no human trials required (no insulin pump has done pre-approval human trials) Led by Paul Diperna and Andy Mann each with over 20 years of FDA submission expe
Slide 13: Product Roadmap: The Path to the Artificial Pancreas
1 MOD1 (Basal with user Bolus) 2 MOD1+ (Cell phone controlled adjusted by algorithm) 3 Product Roadmap. The Path to the Artificial Pancreas MOD2 Dual Chamber (Autonomous, multiple chamber, drug revenue)
Slide 14: In Development: MOD1+ Cell Phone Controlled
In Development MOD1+. Cell Phone Controlled 14 | 10 Enhanced Modular Patch Pump: Cell Phone Controlled 2-Factor Authentication Allows use of user's own cell phone as controller. No dedicated controller required. CGM Integration Allows algorithms to adjust basal rate for meals and exercise. Ease of U
Slide 15: The Future of Care: MOD2
The Future of Care MOD2. The Pivot G-3 is a native multi-chamber pump developed with enhanced ease of use in mind. Designed to be prefilled, the Pivot G-3 will enable Modular Medical to capture drug revenue. Modular Medical will become the one-stop shop for all of a user's diabetes needs. Artificial
Slide 16: The Team
The Team. Chairman, President and CTO Paul DiPerna 35 years of experience in medical device industry CEO Lynn Vos ? Forward thinking healthcare business leader ? Market development expert with track record of success in healthcare, pharma and med tech ? Leader in healthcare marketing and communicati
Slide 17: Investor Relations
Investor Relations ir@modular-medical.com OTCQB:MODD
Slide 18: Appendix
Appendix.
Slide 19: T1D Insulin Pump Comparisons (US Market)
T1D Insulin Pump Comparisons (US Market) . 19 | Product Features t:slim X2 Medtronic 780G Omnipod DASH MOD1 Manufacturer Tandem Diabetes Care Medtronic (MiniMed) Insulet Modular Medical Reservoir Size 300 units/3mL 300 units/3mL 200 units/2mL 300 units/3mL Pump Cost Pump: $4,200 Disposables: $134/mo
Slide 20: Artificial Pancreas Will Be Multi-Chamber
Artificial Pancreas Will Be Multi-Chamber. ? FDA has established 70% Time In Range "no human intervention" standard for AP. ? "Control IQ" study published in NE Journal of medicine barely reached 70% despite announcing meals, sleep, and exercise. ? Prominent KOL's and Algo designers feel 70% TIR wit
Modular Medical — Investor Presentation (September 2021) on 6ix